CN116103219B - 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 - Google Patents
一种雪莲干细胞粉的制备方法及其制得的抑菌剂 Download PDFInfo
- Publication number
- CN116103219B CN116103219B CN202211307694.4A CN202211307694A CN116103219B CN 116103219 B CN116103219 B CN 116103219B CN 202211307694 A CN202211307694 A CN 202211307694A CN 116103219 B CN116103219 B CN 116103219B
- Authority
- CN
- China
- Prior art keywords
- culture
- adopts
- saussurea involucrata
- stem cell
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001145025 Saussurea involucrata Species 0.000 title claims abstract description 53
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 47
- 239000000843 powder Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000022 bacteriostatic agent Substances 0.000 title claims abstract description 28
- 238000001914 filtration Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000004140 cleaning Methods 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000001963 growth medium Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 14
- 240000002853 Nelumbo nucifera Species 0.000 claims description 13
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 13
- 241000251468 Actinopterygii Species 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 11
- 108010035532 Collagen Proteins 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 241000972672 Phellodendron Species 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 10
- 241000721662 Juniperus Species 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000007640 basal medium Substances 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 239000008223 sterile water Substances 0.000 claims description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 6
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000005286 illumination Methods 0.000 claims description 6
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000012879 subculture medium Substances 0.000 claims description 6
- 239000008399 tap water Substances 0.000 claims description 6
- 235000020679 tap water Nutrition 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 5
- 241000576429 Forsythia suspensa Species 0.000 claims description 5
- 229940116229 borneol Drugs 0.000 claims description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 5
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 5
- 241000212948 Cnidium Species 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000012737 fresh medium Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 235000003642 hunger Nutrition 0.000 claims description 3
- 239000003617 indole-3-acetic acid Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 241000205585 Aquilegia canadensis Species 0.000 claims 2
- 241000628997 Flos Species 0.000 claims 2
- 230000035876 healing Effects 0.000 abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 44
- 239000000243 solution Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 244000167230 Lonicera japonica Species 0.000 description 7
- 235000017617 Lonicera japonica Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 6
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 6
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 5
- YDDUMTOHNYZQPO-BBLPPJRLSA-N 1,3-di-O-caffeoylquinic acid Natural products O[C@@H]1C[C@@](C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc1ccc(O)c(O)c1)C(O)=O YDDUMTOHNYZQPO-BBLPPJRLSA-N 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 5
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000012088 reference solution Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001570521 Lonicera periclymenum Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000019305 fibroblast migration Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000453 juniperus communis l. leaf oil Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101100233695 Mus musculus Itch gene Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0025—Culture media for plant cell or plant tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Abstract
本发明涉及一种雪莲干细胞粉的制备方法及其制得的抑菌剂,属于医疗卫生领域,该雪莲干细胞粉的制备方法,其制备步骤如下:选择天山雪莲未分化的根部末端作为外植体,先进行清洗、消毒预处理,之后在一定条件下对其进行初代培养和传代培养,之后在一定条件进行扩大培养,最后进行过滤、干燥等后处理步骤,可以制得具有较佳愈合作用的雪莲根部干细胞冻干粉。将其应用在抑菌剂中,可以使抑菌剂发挥较佳的愈合作用,且有助于获得抑菌和止痒效果更好的抑菌剂。
Description
技术领域
本发明涉及医疗卫生领域,尤其涉及一种雪莲干细胞粉的制备方法及其制得的抑菌剂。
背景技术
天山雪莲是在唯一能够在海拔3000米以上生长的大型草本植物,雪线以上叫天山雪莲,雪线以下为普通石莲,成分、应用具有较大的差别。天山雪莲生命力极强,能在0度左右发芽生长,五到七年才可长成。《本草纲目拾遗》、《中华藏本草》、《藏药志》、《中华本草》、《实用藏药名库》、《晶珠本草》等多部传统医学名著均有记载,维吾尔医、藏医、中医均有广泛应用,主要用于补肾活血、温肾助阳、通络活血、清热解毒、消肿止痛的作用。
天山雪莲由于其独特而又广泛的药理作用,导致人为大量滥采滥挖,再加上其独特的生长环境,天山雪莲已经被列为三级濒危物种。
通过科学研究,现阶段雪莲已经可以离体培养,雪莲培养物多为雪莲离体植物器官例如幼叶进行分化、培养而来,虽然其在日化用品、保健食品、化妆品等方面得到了很好的应用,但是鉴于其良好的应用效果,其仍然有待于进一步研究应用。
本发明特别通过雪莲未分化的根部末端进行体外的离体培养,得到雪莲根干细胞粉末,其具有较佳的促愈作用,且其联合部分海洋产物和特色中药组分形成的抑菌剂在妇科方面有良好的应用前景。
发明内容
本发明为了弥补现有技术的不足,提供了一种雪莲干细胞粉的制备方法及其制得的抑菌剂,其选择雪莲未分化根部基于本申请培养方法下,可以获得具有较好促愈效果的雪莲干细胞粉,其可以应用在抑菌剂中,使抑菌剂发挥良好的促愈效果、止痒效果和抑菌效果。
本发明为解决上述技术问题所采用的技术方案是:
一种雪莲干细胞粉的制备方法,制备步骤如下:
S1:选择天山雪莲未分化的根部末端作为外植体,进行清洗、消毒得预处理物;
S2:将预处理物切块后进行初代培养得初代培养物,初代培养条件为:采用MS基础培养基,并在其中添加0.05mg/l的a-萘乙酸、2mg/l的6-BA、3%重量百分比的蔗糖、0.5%重量百分比的琼脂、0.01mg/ml的吲哚乙酸,培养温度为26±1℃,培养pH值在5.8,培养时间为15-18天;
S3:从初代培养物中选取颗粒细小、形状一致、分散性好、生长旺盛、颜色鲜亮的B类黄白色愈伤组织,于无菌状态下先后用60、80目不锈钢筛网过滤,选择60-80目之间的愈伤组织以2g/30ml接种浓度接入MS基础培养基中,饥饿培养数天后转移到新的培养基上进行传代培养,传代培养条件为:采用MS基础培养基,并在其中添加5mg/l的a-萘乙酸、0.5mg/l的6-BA、3%重量百分比的蔗糖、0.45%重量百分比的琼脂;培养温度为24±1℃,光照周期为12 h/d,光照强度为80μmol·m-2·s-1,培养周期为16天;
S4:将传代培养物转移到新的传代培养基中,培养1-2天后过滤,去掉滤渣,重新加入到新的传代培养基中,并加入非生物诱导剂,进一步扩大培养,其中非生物诱导剂采用硝普钠、水杨酸中的至少一种;
S5:将扩大培养后的雪莲干细胞进行离心过滤,之后冻存并冷冻干燥,最后使用粉碎机进行粉碎、过筛,即得。
进一步的,S1的具体预处理过程为:(1)将外植体先用自来水浸泡10min,之后用自来水、纯水、超纯水各清洗三次,之后用滤纸吸干清洗好的外植体表面水分;(2)用75%酒精浸泡1min,无菌水清洗2次;(3)用2%的HgCl2浸泡15min,无菌水清洗5次,之后将消毒后的材料放入无菌培养皿中,用无菌滤纸吸干水分备用。
进一步的,非生物诱导剂采用质量比为1:1的硝普钠和水杨酸。
进一步的,传代培养方式采用半连续培养,其原有的培养基:新鲜培养基为1:3。
本申请还提供了一种抑菌剂,通过如下步骤制备:
A1:将刺柏、黄柏、连翘、山银花、苦参、蛇床子、海螵蛸分别以其自身10倍重量的水提取2次,每次提取1h,得到刺柏提取液、黄柏提取液、连翘提取液、山银花提取液、苦参提取液、蛇床子提取液、海螵蛸提取液;
A2:将上述提取液混合,过滤后浓缩得60℃时相对密度为1.10-1.15的清膏,放冷;
A3:加入乙醇使其含量为70%,低温静置48h,取上清液,回收乙醇至无醇味;
A4:加水至800ml,加入上述制备方法制得雪莲干细胞粉,加热搅拌至溶解,低温静置24h,取上清液过滤备用;
A5:将冰片、薄荷脑、醋酸氯已定加入到50ml丙二醇中,之后与5ml吐温-80混合,搅拌溶解后,与A4的备用溶液混合;
A6:按照规定计量加入海藻酸钠、鱼胶原蛋白、溶菌酶,并补水至1000ml,之后静置24h后取上清液,即得;
其中,按照重量份数计,雪莲干细胞粉采用0.8-1.2份,刺柏采用18-21份,黄柏采用14-16份,连翘采用14-16份,山银花采用8-12份,苦参采用15-16份,蛇床子采用9-12份,海螵蛸采用9-11份,冰片采用0.9-1.2份,薄荷脑采用0.8-1.2份,海藻酸钠采用0.8-1.2份,鱼胶原蛋白采用0.9-1.2份,醋酸氯已定采用1.8-2.1份,溶菌酶采用0.9-1.1份。
优选的,按照重量份数计,雪莲干细胞粉采用1份,刺柏采用20份,黄柏采用15份,连翘采用15份,山银花采用10份,苦参采用15份,蛇床子采用10份,海螵蛸采用10份,冰片采用1份,薄荷脑采用1份,海藻酸钠采用1份,鱼胶原蛋白采用1份,醋酸氯已定采用2份,溶菌酶采用1份。
本发明采用上述结构,所具有的优点是:选择雪莲未分化的根部作为外植体,并通过本申请制备方法来制备雪莲根部干细胞冻干粉,可以获得具有较佳促愈作用的雪莲根部干细胞冻干粉。
将制得雪莲根部干细胞冻干粉,应用在抑菌剂中,除了可以发挥较佳的促愈作用,还有助于发挥抑菌剂的抑菌和止痒的作用。
附图说明
图1为本发明空白组在0h和40h时的促愈实验结果;
图2为本发明实验样品在0h和40h时的促愈实验结果;
图3为本发明对比样品1在0h和40h时的促愈实验结果;
图4为本发明对比样品2在0h和40h时的促愈实验结果;
图5为本发明黄酮类化合物含量测定的标准曲线。
具体实施方式
为能清楚说明本方案的技术特点,下面通过具体实施方式,并结合附图,对本发明进行详细阐述。在下面的描述中阐述了很多具体细节以便于充分理解本申请,但是本申请还可以采用其他不同于在此描述的其他方式来实施,因此,本申请的保护范围并不受下面公开的具体实施例的限制。
(一)样品
将本申请制备方法设为方法a,常规雪莲干细胞粉的制备方法设为方法b,进行如下样品的制备:
实验样品:通过方法a制得的雪莲根部干细胞冻干粉
对比样品1:通过方法a制得的雪莲幼芽干细胞冻干粉
对比样品2:雪莲粉
对比样品4:通过方法b制得的雪莲根部干细胞冻干粉
其中,方法a的制备步骤如下:S1:选择天山雪莲未分化的根部末端作为外植体,并进行如下处理:(1)将外植体先用自来水浸泡10min,之后用自来水、纯水、超纯水各清洗三次,之后用滤纸吸干清洗好的外植体表面水分;(2)用75%酒精浸泡1min,无菌水清洗2次;(3)用2%的HgCl2浸泡15min,无菌水清洗5次,之后将消毒后的材料放入无菌培养皿中,用无菌滤纸吸干水分备用;S2:将预处理物切块后进行初代培养得初代培养物,初代培养条件为:采用MS基础培养基,并在其中添加0.05mg/l的a-萘乙酸、2mg/l的6-BA、3%重量百分比的蔗糖、0.5%重量百分比的琼脂、0.01mg/ml的吲哚乙酸,培养温度为26±1℃,培养pH值在5.8,培养时间为15-18天;S3:从初代培养物中选取颗粒细小、形状一致、分散性好、生长旺盛、颜色鲜亮的B类黄白色愈伤组织,于无菌状态下先后用60、80目不锈钢筛网过滤,选择60-80目之间的愈伤组织以2g/30ml接种浓度接入MS基础培养基中中,饥饿培养数天后转移到新的培养基上进行传代培养,传代培养方式采用半连续培养,其原有培养基:新鲜培养基为1:3,传代培养条件为:采用MS基础培养基,并在其中添加5mg/l的a-萘乙酸、0.5mg/l的6-BA、3%重量百分比的蔗糖、0.45%重量百分比的琼脂;培养温度为24±1℃,光照周期为12 h/d,光照强度为80μmol·m-2·s-1,培养周期为16天;S4:将传代培养物转移到新的传代培养基中,培养1-2天后过滤,去掉滤渣,重新加入到新的传代培养基中,并加入非生物诱导剂,进一步扩大培养,其中非生物诱导剂采用质量比为1:1的硝普钠和水杨酸的混合液;S5:将扩大培养后的雪莲干细胞进行离心过滤,之后冻存并冷冻干燥,最后使用粉碎机进行粉碎、过筛,即得。
方法b的制备方法如下:(1)取样品,用自来水流水冲洗2h;用浓度70%酒精表面消毒10s,无菌水冲洗3次;用浓度0.1%升贡溶液分别消毒4、6、8、10min后,用无菌水冲洗3次,洗去植物表面的升贡残液,以构成不同的消毒处理;将消毒材料放入无菌培养皿中,用无菌滤纸吸干水分备用。(2)无菌条件下,将消毒后雪莲幼根切成约0.5cm*0.5cm大小,接种在固体培养基上。接种时,背面与培养基接触,每瓶1块。培养温度为25℃,培养pH值6.0,培养时间为20天。(3)待培养至20天时,将形成层细胞转移至液态培养基的烧瓶中培养,并时刻在显微镜下观察细胞的聚集状态和程度。(4)将在烧瓶中培养的干细胞移入20L的生物反应器内放大培养,在 25℃不间断搅拌。在培养至第10d时,向生物反应器内注入蔗糖、甲基茉莉酮酸酯和无菌磁化水的混合液,以补充后期营养加速干细胞生长。(5)将培养液用1um过滤器过滤,去掉培养液,将截留的细胞系培养物取出,放入-80℃超低温速冻2h,取出解冻30min;再放入-80℃超低温速冻,依次3次;最后一次解冻后利用超声波破碎仪破碎细胞,过滤器过滤,收集滤液,旋转式真空蒸发器内浓缩,将浓缩液过滤除菌,然后进行冻于处理,冻干温度为-20℃,真空度为50Pa,冻干时间为48小时,即得。
(二)促愈实验
进行实验样品、对比样品1-3的促愈实验,实验方法和实验结果如下:
1、实验方法
(1)先将样品加水溶解,之后吸取适量样品药物于10mlEP管中,使用微孔滤器在无菌操作台上过滤,之后将样品药物用含2%胎牛血清的1640培养液做10、40、160倍梯度稀释,编号后置4℃冰箱中备用。
(2)液氮冻存的3T3细胞加入离心管中,在37℃水浴于1min内迅速摇晃使其融化;取出冰箱中的冻存管,打开盖子,用吸管吸出细胞悬液,加到离心管并滴加10倍以上培养液,混匀;800r·min-1, 5min离心后,弃去上清液,加入含10%小牛血清培养液重悬细胞,计数,调整细胞密度,接种培养瓶,37℃培养箱静置培养;待长成单层后,用0.25%胰酶消化,以1:2传代,细胞长成单层时用于实验。此处10%的胎牛血清1640培养基是为了将离心的3T3细胞重悬,方便计数,并进行密度调整。
(3)将细胞密度为1×105个/mL的3T3细胞悬液接种在96孔板(弃四周孔),每孔100uL,四周加入等体积的无菌蒸馏水。37℃培养箱静置培养18 h后,弃去培养液用1000uL枪头在中央垂直划一均匀痕迹,PBS 缓冲液洗涤划落的细胞碎片,实验分四组即正常细胞组(只划痕不加药)、高浓度药物组、中浓度药物组、低浓度药物组,正常对照含2 %胎牛血清的1640培养基进行培养,每组均加样100uL,每组设6个复孔。分别在划痕后0h、40h时于倒置显微镜下观察并拍照,其中显微镜观察倍数如下,目镜:10x,物镜:10x。
2、实验结果
对照组的上皮细胞在生理状态下,形成单层或复层上皮,在病理状态下,如创伤愈合,细胞迁移的时候,以侧向运动为主,通过图1可知,对照组细胞划痕40h后并未出现明显的侧向迁移作用。
通过图2可知,对于实验样品来说,160倍稀释后作用于成纤维细胞,培养40h后,该浓度下的细胞发生明显迁移,这表明加入其具有显著促进成纤维细胞迁移的作用;另外,10倍和40倍稀释条件下,细胞也发生了明显迁移效果(图略),这说明实验样品具有显著促进成纤维细胞迁移的作用。
通过图3可知,对于对比样品1来说,160倍稀释后作用于成纤维细胞,培养40h后,发现该浓度下细胞发生了一定程度的迁移,迁移程度比对照组强,比实验组弱;另外,10倍和40倍稀释条件下,细胞也发生了一定程度的迁移效果(图略)。
通过图4可知,对于对比样品2来说,160倍稀释后作用于成纤维细胞,培养40h后,发现该浓度下细胞迁移程度较低,变化不明显,但强于对照组,这表明对比样品2具有促进成纤维细胞迁移的作用,但促迁移的能力较弱;另外,10倍和40倍稀释条件下,细胞对比样品2促进成纤维细胞迁移的能力也较弱(图略)。
对于对比样品3来说,160倍稀释后作用于成纤维细胞,发现该浓度下细胞发生了一定程度的迁移(图略),但是迁移程度较实验样品和对比样品1低,较对比样品2强,这说明培养方法对细胞迁移有一定的影响。
综上可知,促愈实验进行40h后,各样品对伤口促愈效果的影响程度为:实验样品的促愈效果最好,对比样品1次之,对比样品3再之,对比样品2最弱。这说明以天山雪莲未分化根部作为外植体,通过本申请制备方法制得的雪莲干细胞(根部)冻干粉,具有较好的愈合作用。
(三)有效成分含量的测定
由于黄酮类化合物、紫丁香苷、1,5-二咖啡酰奎尼酸是雪莲花中含有的具有消炎、消肿等作用的成分,而这些成分是有利于患部愈合的,因此对实验样品、对比样品1-3分别进行以上三种成分的含量测定。
1、测定方法
(1)黄酮类化合物的含量测定
对照品溶液的制备:精密称取芦丁(属于黄酮类化合物)对照品适量,甲醇制定1mg/ml的对照品溶液。
标准曲线:分别量取对照品溶液0.2、0.4、0.6、0.8、1.2、2.0、3.0ml于25ml容量瓶中,分别加入水至6ml,加10%硝酸铝1ml,摇匀,放置8分钟,加氢氧化钠试液10ml,加水至刻度,摇匀,放置15分钟,以相应试剂为空白照紫外可见光分光光度法于500nm测定吸光度。以吸光度为纵坐标,浓度为横坐标绘制标准曲线,具体见图5。
精密称取各样品0.25g,置锥形瓶中,加甲醇25ml,超声30分钟,用甲醇补足减失的重量,取续滤液5ml至25ml比色管中,自“加水至6ml”同法操作,测定吸光度,并在标准曲线读取芦丁的量,计算,即得。
通过上述测定方法测得的实验样品、对比样品1-3的芦丁含量见表1。
(2)紫丁香苷含量的测定
色谱条件:安捷伦1200液相系统,Agilent ODS C18色谱柱( 4.6mm×250mm,5μm);以乙腈为流动相A,以0.02M磷酸二氢钾溶液为流动相B,梯度洗脱(0~20min,8%~10% A;20~50 min,10%~30% A);柱温30℃;流速为1.0mL/min;检测波长265nm;进样量为20μL。
对照品溶液的制备:取紫丁香苷标准品适量,加10%乙腈溶液,配制含量分别为0.01mg/mL、0.005mg/mL、0.025mg/mL的混合标准品溶液。
标准曲线:取标准品溶液,在进样量分别为4μL、10μL、16μL、20μL、40μL、60μL条件下测定峰面积,折算进样量20μL进行测定。以质量浓度(μg /mL)为纵坐标,峰面积(AU×S)为横坐标,绘制各成分标准曲线(省略视图)。
供试品溶液的制备:取样品0.1g,加10%乙腈水溶液100mL,超声提取30min,取上清液过滤膜,待测。精密量取供试品溶液、混合对照品溶液各 20μL,注入液相色谱仪,按预设的色谱条件进样检测。
通过上述测定方法测得的实验样品、对比样品1-3的紫丁香苷含量见表1。
(3)1,5-二咖啡酰奎尼酸含量的测定
色谱条件:安捷伦1200液相系统,Agilent ODS C18色谱柱( 4.6mm×250mm,5μm);以乙腈流动相为A,以0.02M磷酸二氢钾溶液为流动相B,梯度洗脱(0~20min,8%~10% A;20~50 min,10%~30% A);柱温 30℃;流速为1.0mL/min;检测波长265nm;进样量为20μL。
对照品溶液的制备:取1,5-二咖啡酰奎尼酸标准品适量,加 10%乙腈溶液,配制含量分别为0.01mg/mL、0.005mg/mL、0.025mg/mL的混合标准品溶液。
标准曲线:取标准品溶液,在进样量分别为4μL、10μL、16μL、20μL、40μL、60μL条件下测定峰面积,折算进样量20μL进行测定。以质量浓度(μg /mL) 为纵坐标,峰面积(AU×S)为横坐标,绘制各成分标准曲线(省略视图)。
供试品溶液的制备:取本品0.1g,加10%乙腈水溶液100mL,超声提取30min,取上清液过滤膜,待测。精密量取供试品溶液、混合对照品溶液各 20μL,注入液相色谱仪,按预设的色谱条件进样检测。
2、测定结果
通过上述测定方法测得的实验样品、对比样品1-3的黄酮类化合物的含量、紫丁香苷的含量、1,5-二咖啡酰奎尼酸的含量见表1。
表1 实验样品、对比样品1-3中三种成分的含量
通过表1可知,实验样品中黄酮类化合物(芦丁)、紫丁香苷、1,5-二咖啡酰奎尼酸三种成分的含量明显高于对比样品1和对比样品3,远远高于对比样品2。这表明以天山雪莲未分化的根部为外植体,通过本申请制备方法来制备雪莲干细胞冻干粉,利于获得以上三种高含量成分的天山雪莲根部干细胞冻干粉。结合愈合实验结果,可以推测上述三种成分的提高可能是影响愈合实验结果的因素。
(四)抑菌剂的相关实验
1、抑菌剂制备方法如下:
A1:将刺柏、黄柏、连翘、山银花、苦参、蛇床子、海螵蛸分别以其自身10倍重量的水提取2次,每次提取1h,得到刺柏提取液、黄柏提取液、连翘提取液、山银花提取液、苦参提取液、蛇床子提取液、海螵蛸提取液;A2:将上述提取液混合,过滤后浓缩得相对密度为1.10-1.15(60℃)的清膏,放冷;A3:加入乙醇使其含量为70%,低温静置48h,取上清液,回收乙醇至无醇味;A4:加水至800ml,加入雪莲根部干细胞冻干粉,加热搅拌至溶液,低温静置24h,取上清液过滤备用;A5:将冰片、薄荷脑、醋酸氯已定加入到50ml丙二醇中,之后与5ml吐温-80混合,搅拌溶解后,与A4的备用溶液混合;A6:按照规定计量加入海藻酸钠、鱼胶原蛋白、溶菌酶,并补水至1000ml,之后静置24h后取上清液,即得;其中,按照重量份数计,雪莲干细胞粉采用1份,刺柏采用20份,黄柏采用15份,连翘采用15份,山银花采用10份,苦参采用15份,蛇床子采用10份,海螵蛸采用10份,冰片采用1份,薄荷脑采用1份,海藻酸钠采用1份,鱼胶原蛋白采用1份,醋酸氯已定采用2份,溶菌酶采用1份。
将通过上述制备方法制得的抑菌剂1(含雪莲根部干细胞粉)、抑菌剂2(不含雪莲根部干细胞粉) 分别进行抑菌实验、止痒实验和愈合实验。
2、抑菌实验
选择白色念珠菌、大肠埃希菌和金黄色葡萄球菌3种易引起阴道炎的真菌及细菌进行抑菌试验,分别考察抑菌剂1和抑菌剂2供试品在体外对3种菌的抑菌效果,以及在加速试验条件下放置3个月的供试品抑菌效果。
(1)抑菌率实验
实验过程:将金黄色葡萄球菌、大肠埃希菌菌种接种于斜面营养培养基上,30 ℃培养24 h;白色念珠菌菌种接种于斜面沙氏培养基上,30 ℃培养 48 h。分别用无菌 PBS将菌苔冲洗下来,调整浓度为 3x108CFU/ml,备用。取10 uL菌种悬浮液,稀释至10 mL,得到浓度约为 3.8x105CFU/ml 的菌液。
分别取上述菌液0.1 mL,加至含5 mL抑菌剂1和抑菌剂2及无菌生理盐水对照液的试管内,充分反应2 min。取反应后的各溶液0.5mL 至含 5 mL PBS 的试管内,充分混匀。取混匀后的溶液,分别稀释至1、5 、10倍。取不同稀释倍数的各溶液0.5 mL 至培养皿中,分别倾入40 ℃左右的营养琼脂培养基或沙氏培养基20 mL,转动培养皿使之混合均匀,培养基凝固后翻转平皿,30 ℃培养24、48 h,作活菌菌落计数,计算抑菌率,结果见表2。
(2)抑菌性能稳定性试验
取3批供试品,置于加速试验条件(37-40 ℃、相对结果见表2湿度>75%恒温箱内)3 个月,进行抑菌性能测试。抑菌率测定方法同上,结果见表2。
表2 洗液1和洗液2的抑菌实验结果
通过表2结果可知,抑菌剂1供试品对3种菌均抑菌率>95%,抑菌剂2供试品对3种菌均抑菌率在90%左右,由此可知抑菌剂2具有较强的抑菌能力;加速实验放置3个月后,抑菌剂1供试品对 3种菌均抑菌率>85%,抑菌剂2供试品对3种菌均抑菌率在85%左右,这表明2个样品均仍具有抑菌作用,且稳定性较好。
3、止痒实验
小鼠前处理:选用试验用小鼠,体质量26-28 g,24只,随机分组,每组6只,雌雄各半,用脱毛膏将小鼠腹部,脱毛4 cmx3 cm,以清水擦净。试验用洗液组于脱毛处分别涂扶样品0.2 mL,面积约12 cm,用无菌纱布覆盖,胶布绕腰部固定,松紧适度,每日给样2次,共5d,期间正常喂食饮水。
方法及统计:于末次给药40min后除去样品,除了空白组外其余各组给每只小鼠尾静脉注射 0.025%低分子右旋糖酐0.05 mL·10g(1.25mg·kg)。尾静脉注射右旋糖酐后小鼠可发生阵发性皮肤瘙痒,表现为前爪挠头部,后爪挠躯干,嘴巴咬身体各部位及尾巴。对30 min 内各组小鼠阵发性瘙痒发作次数及累计持续时间进行数据统计学处理,评价药物的止痒作用,评价结果见表3。
表3 抑菌剂1和抑菌剂2的止痒实验结果
组别 | 小鼠瘙痒(发作次数/s) | 小鼠瘙痒(发作时间/min) |
抑菌剂1 | 9±3 | 15±3 |
抑菌剂2 | 22±4 | 30±4 |
空白组 | 0 | 0 |
由表3可知,对30 min 内各组小鼠阵发性瘙痒发作次数及累计持续时间进行数据统计学处理,评价洗液的止痒作用。其中,抑菌剂1组小鼠瘙痒次数最少及发作时间最短,说明抑菌剂1组具有一定的止痒作用,且止痒效果优于抑菌剂2组。
4、促愈实验
促愈实验过程同雪莲根部干细胞粉末的促愈实验,样品选择抑菌剂1和抑菌剂2,实验结果表明,对于抑菌剂1,采用10,40,160倍稀释后作用于成纤维细胞,观察高、中、低浓度下的细胞均发生明显迁移,表明抑菌剂1具有显著的促进成纤维细胞迁移的作用;对于抑菌剂2,采用10,40,160倍稀释后作用于成纤维细胞,观察高、中、低浓度下的细胞迁移程度不明显,远低于抑菌剂1,这表明抑菌剂中起愈合作用的成分主要是雪莲根部干细胞冻干粉。
综上可知,抑菌剂1在抑菌、促愈、止痒各方面的效果要优于抑菌剂2,这说明抑菌剂中加入本申请制得的雪莲根部干细胞冻干粉,不仅能够发挥较佳的愈合作用,且在抑菌和止痒方面也有帮助,该抑菌剂联合部分海洋产物和特色中药组分形成,在妇科抑菌方面具有良好的应用前景。
上述具体实施方式不能作为对本发明保护范围的限制,对于本领域技术领域的技术人员来说,对本发明实施方式所做出的任何替代改进或变换均落在本发明的保护范围内。本发明未详述之处,均为本技术领域技术人员公知技术。
Claims (6)
1.一种雪莲干细胞粉的制备方法,其特征在于,制备步骤如下:
S1:选择天山雪莲未分化的根部末端作为外植体,进行清洗、消毒得预处理物;
S2:将预处理物切块后进行初代培养得初代培养物,初代培养条件为:采用MS基础培养基,并在其中添加0.05mg/l的a-萘乙酸、2mg/l的6-BA、3%重量百分比的蔗糖、0.5%重量百分比的琼脂、0.01mg/ml的吲哚乙酸,培养温度为26±1℃,培养pH值在5.8,培养时间为15-18天;
S3:从初代培养物中选取颗粒细小、形状一致、分散性好、生长旺盛、颜色鲜亮的B类黄白色愈伤组织,于无菌状态下先后用60、80目不锈钢筛网过滤,选择60-80目之间的愈伤组织以2g/30ml接种浓度接入MS基础培养基中,饥饿培养数天后转移到新的培养基上进行传代培养,传代培养条件为:采用MS基础培养基,并在其中添加5mg/l的a-萘乙酸、0.5mg/l的6-BA、3%重量百分比的蔗糖、0.45%重量百分比的琼脂;培养温度为24±1℃,光照周期12 h/d,光照强度80μmol·m-2·s-1,培养周期为16天;
S4:将传代培养物转移到新的传代培养基中,培养1-2天后过滤,去掉滤渣,重新加入到新的传代培养基中,并加入非生物诱导剂,进一步扩大培养,其中非生物诱导剂采用硝普钠、水杨酸中的至少一种;
S5:将扩大培养后的雪莲干细胞进行离心过滤,之后冻存并冷冻干燥,最后使用粉碎机进行粉碎、过筛,即得。
2.根据权利要求1所述的雪莲干细胞粉的制备方法,其特征在于,S1的具体预处理过程为:(1)将外植体先用自来水浸泡10min,之后用自来水、纯水、超纯水各清洗三次,之后用滤纸吸干清洗好的外植体表面水分;(2)用75%酒精浸泡1min,无菌水清洗2次;(3)用2%的HgCl2浸泡15min,无菌水清洗5次,之后将消毒后的材料放入无菌培养皿中,用无菌滤纸吸干水分备用。
3.根据权利要求1所述的雪莲干细胞粉的制备方法,其特征在于,步骤S4中,非生物诱导剂采用质量比为1:1的硝普钠和水杨酸。
4.根据权利要求1所述的雪莲干细胞粉的制备方法,其特征在于,步骤S3中,传代培养方式采用半连续培养,其原有的培养基:新鲜培养基为1:3。
5.一种抑菌剂,其特征在于,通过如下步骤制备:
A1:将刺柏、黄柏、连翘、山银花、苦参、蛇床子、海螵蛸分别以其自身10倍重量的水水煮提取2次,每次提取1h,得到刺柏提取液、黄柏提取液、连翘提取液、山银花提取液、苦参提取液、蛇床子提取液、海螵蛸提取液;
A2:将上述提取液混合,过滤后浓缩得60℃时相对密度为1.10-1.15的清膏,放冷;
A3:加入乙醇使其含量为70%,低温静置48h,取上清液,回收乙醇至无醇味;
A4:加水至800ml,加入权利要求1-4任一项制备方法制备的雪莲干细胞粉,加热搅拌至溶液,低温静置24h,取上清液过滤备用;
A5:将冰片、薄荷脑、醋酸氯已定加入到50ml丙二醇中,之后与5ml吐温-80混合,搅拌溶解后,与A4的备用溶液混合;
A6:按照规定计量加入海藻酸钠、鱼胶原蛋白、溶菌酶,并补水至1000ml,之后静置24h后取上清液,即得;
其中,按照重量份数计,雪莲干细胞粉采用0.8-1.2份,刺柏采用18-21份,黄柏采用14-16份,连翘采用14-16份,山银花采用8-12份,苦参采用15-16份,蛇床子采用9-12份,海螵蛸采用9-11份,冰片采用0.9-1.2份,薄荷脑采用0.8-1.2份,海藻酸钠采用0.8-1.2份,鱼胶原蛋白采用0.9-1.2份,醋酸氯已定采用1.8-2.1份,溶菌酶采用0.9-1.1份。
6.根据权利要求5所述的抑菌剂,其特征在于,按照重量份数计,雪莲干细胞粉采用1份,刺柏采用20份,黄柏采用15份,连翘采用15份,山银花采用10份,苦参采用15份,蛇床子采用10份,海螵蛸采用10份,冰片采用1份,薄荷脑采用1份,海藻酸钠采用1份,鱼胶原蛋白采用1份,醋酸氯已定采用2份,溶菌酶采用1份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211307694.4A CN116103219B (zh) | 2022-10-25 | 2022-10-25 | 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211307694.4A CN116103219B (zh) | 2022-10-25 | 2022-10-25 | 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116103219A CN116103219A (zh) | 2023-05-12 |
CN116103219B true CN116103219B (zh) | 2023-07-04 |
Family
ID=86262062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211307694.4A Active CN116103219B (zh) | 2022-10-25 | 2022-10-25 | 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116103219B (zh) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1961650A (zh) * | 2005-11-11 | 2007-05-16 | 大连普瑞康生物技术有限公司 | 新疆雪莲细胞组织培养物及其大规模继代培养的方法 |
CN101115493A (zh) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | 生发剂 |
CN101773071A (zh) * | 2010-01-19 | 2010-07-14 | 烟台汇鹏生物科技有限公司 | 天山雪莲愈伤组织培养方法 |
CN104498425A (zh) * | 2014-11-28 | 2015-04-08 | 广州赛莱拉干细胞科技股份有限公司 | 雪莲干细胞的分离培养方法及在制备抗衰老产品中的应用 |
CN104855978A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 抗衰老非全营养配方食品 |
CN105062810A (zh) * | 2015-07-22 | 2015-11-18 | 王荣贵 | 一种雪莲配制酒及其制备方法 |
CN108504623A (zh) * | 2018-04-28 | 2018-09-07 | 大连普瑞康生物技术有限公司 | 一种水母雪莲高产黄酮细胞系及其制备方法 |
CN108671002A (zh) * | 2018-05-31 | 2018-10-19 | 南京中生生物科技有限公司 | 一种含雪莲培养物提取物的组合物及其应用 |
CN108815100A (zh) * | 2018-08-09 | 2018-11-16 | 广州暨南生物医药研究开发基地有限公司 | 含有艾叶干细胞提取物的抑菌止痒护肤品及其制备方法 |
CN109010195A (zh) * | 2018-10-13 | 2018-12-18 | 陈洁珍 | 一种美白除皱祛疤修复护肤霜及其制备方法 |
CN110923190A (zh) * | 2019-11-28 | 2020-03-27 | 大连普瑞康生物技术有限公司 | 一种提高雪莲细胞培养物黄酮苯丙素类化合物的方法 |
CN110946817A (zh) * | 2018-09-25 | 2020-04-03 | 元穗生物科技(上海)有限公司 | 天然草本女士私处专用皮肤黏膜消毒剂 |
CN111374936A (zh) * | 2020-04-02 | 2020-07-07 | 安赛搏(重庆)生物技术有限公司 | 多元液体体系制备雪莲细胞提取物的方法及其用途 |
WO2023035479A1 (zh) * | 2021-09-07 | 2023-03-16 | 北京中医药大学 | 中药复合物、中药有效组分组合物、化合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132021A1 (en) * | 1997-04-30 | 2002-09-19 | Ilya Raskin | Elicited plant products |
-
2022
- 2022-10-25 CN CN202211307694.4A patent/CN116103219B/zh active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115493A (zh) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | 生发剂 |
CN1961650A (zh) * | 2005-11-11 | 2007-05-16 | 大连普瑞康生物技术有限公司 | 新疆雪莲细胞组织培养物及其大规模继代培养的方法 |
CN101773071A (zh) * | 2010-01-19 | 2010-07-14 | 烟台汇鹏生物科技有限公司 | 天山雪莲愈伤组织培养方法 |
CN104498425A (zh) * | 2014-11-28 | 2015-04-08 | 广州赛莱拉干细胞科技股份有限公司 | 雪莲干细胞的分离培养方法及在制备抗衰老产品中的应用 |
CN104855978A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 抗衰老非全营养配方食品 |
CN105062810A (zh) * | 2015-07-22 | 2015-11-18 | 王荣贵 | 一种雪莲配制酒及其制备方法 |
CN108504623A (zh) * | 2018-04-28 | 2018-09-07 | 大连普瑞康生物技术有限公司 | 一种水母雪莲高产黄酮细胞系及其制备方法 |
CN108671002A (zh) * | 2018-05-31 | 2018-10-19 | 南京中生生物科技有限公司 | 一种含雪莲培养物提取物的组合物及其应用 |
CN108815100A (zh) * | 2018-08-09 | 2018-11-16 | 广州暨南生物医药研究开发基地有限公司 | 含有艾叶干细胞提取物的抑菌止痒护肤品及其制备方法 |
CN110946817A (zh) * | 2018-09-25 | 2020-04-03 | 元穗生物科技(上海)有限公司 | 天然草本女士私处专用皮肤黏膜消毒剂 |
CN109010195A (zh) * | 2018-10-13 | 2018-12-18 | 陈洁珍 | 一种美白除皱祛疤修复护肤霜及其制备方法 |
CN110923190A (zh) * | 2019-11-28 | 2020-03-27 | 大连普瑞康生物技术有限公司 | 一种提高雪莲细胞培养物黄酮苯丙素类化合物的方法 |
WO2021103863A1 (zh) * | 2019-11-28 | 2021-06-03 | 大连普瑞康生物技术有限公司 | 一种提高雪莲细胞培养物黄酮苯丙素类化合物的方法 |
CN111374936A (zh) * | 2020-04-02 | 2020-07-07 | 安赛搏(重庆)生物技术有限公司 | 多元液体体系制备雪莲细胞提取物的方法及其用途 |
WO2023035479A1 (zh) * | 2021-09-07 | 2023-03-16 | 北京中医药大学 | 中药复合物、中药有效组分组合物、化合物及其应用 |
Non-Patent Citations (8)
Title |
---|
天山雪莲干细胞巅峰供氧 歆之白,从内氧出瓷白无痕美肌;丝琳・妮尔;;医学美学美容(财智)(09);全文 * |
天山雪莲悬浮培养细胞中紫丁香普、绿原酸和1,5-二咖啡酞奎尼酸的生物合成调控;陈日道 等;《中国中药杂志》;全文 * |
天山雪莲组培苗生根培养体系的优化;吕亚丽 等;《中国药学杂志》;全文 * |
天山雪莲细胞培养物对RANKL诱导破骨细胞的影响;王南;唐琴;姬芳玲;窦佳;包永明;;中成药(01);全文 * |
新疆天山雪莲组培快繁技术的建立;赵海清 等;《安徽农业科学》;全文 * |
濒危药用植物天山雪莲的根段组织培养与植株再生;江丽丽 等;《石河子大学学报(自然科学版)》;全文 * |
生物技术在几种植物生物活性物质生产中的应用;张广伦;顾龚平;张卫明;;中国野生植物资源(04);全文 * |
稳定高产黄酮的水母雪莲细胞系的建立;胡显文;高丽华;胥照平;陈惠鹏;李佐虎;;高技术通讯(06);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116103219A (zh) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112494713A (zh) | 一种益生菌结合氧化白及多糖-壳聚糖复合水凝胶及其制备方法和用途 | |
CN101508711A (zh) | 从含羞草中分离纯化黄酮苷单体的方法 | |
CN103609439B (zh) | 不同菌种对人参发状根的影响及应用方法 | |
CN116103219B (zh) | 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 | |
CN115109739B (zh) | 一种快速高密度培养沙漠蔷薇悬浮细胞高产绿原酸的方法 | |
EP0197525B1 (en) | Plant culture cell and use thereof | |
CN106538394A (zh) | 一种红豆杉培养基及其制备方法 | |
CN106580769A (zh) | 一种抑菌护齿牙膏 | |
CN117064960A (zh) | 一种基于石崖茶的黄酮类提取物及其制备方法和应用 | |
CN101451122B (zh) | 褐点石斑鱼鳔细胞系的构建方法 | |
CN114557336A (zh) | 可提高组织原代分离数量及活性的组织处理液及其制备方法和应用 | |
CN110938582A (zh) | 一种可提高细胞增殖活性的培养基及其制备方法 | |
CN1981030B (zh) | 使细胞治疗中使用的细胞长期生长和存活的卵泡液 | |
CA1164818A (en) | Tissue culture substrate | |
CN113244276B (zh) | 桑黄或桑黄提取物作为新型冠状病毒治疗药物或抗病毒制剂的用途 | |
CN110327273B (zh) | 美白组合物、美白护肤品及其制备方法 | |
CN113943612B (zh) | 一种石墨烯抑菌面料用油渍清洁凝胶及其制备方法 | |
CN115282166B (zh) | 鹿茸干细胞及其外泌体在制备抗疤痕产品中的应用 | |
CN118615219B (zh) | 一种含莲须提取物的皮肤抗衰老复合物及其制备方法 | |
CN100393318C (zh) | 一种积雪苷外用无菌粉剂及制备方法 | |
RU2762431C1 (ru) | Способ выделения биологически активных веществ антимикробного действия из клеточных культур элеутерококка колючего eleutherococcus senticosus rupr. maxim. | |
CN108912235B (zh) | 一种砂引草多糖制备方法及植物抗盐调节剂 | |
CN116270803A (zh) | 香椿花提取物在制备抗氧化的药物中的应用 | |
CN116173102A (zh) | 香椿花提取物在制备抗热应激的药物中的应用 | |
CN116159001A (zh) | 一种用于养肤的复合精油的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |